Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus

NCT01517243 is registered in ClinicalTrials.gov with Dartmouth-Hitchcock Medical Center as lead sponsor.

NCT NCT01517243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01517243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus
Lead sponsor
Dartmouth-Hitchcock Medical Center
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2010
Completion date
August 20, 2018
Enrollment
37 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma